Aqua Pharmaceuticals, An Almirall Company
Aqua Pharmaceuticals is a specialty dermatology company focusing on acquiring, developing and marketing prescription medical dermatology products in the United States. Currently marketed products include: ACTICLATE¬ (doxycycline hyclate USP) Tablets, CORDRAN¬ (flurandrenolide USP) Lotion, Cream, and Ointment, 0.05%, FLUOROPLEX¬ (fluorouracil) 1% Topical Cream, XOLEGEL¬ (ketaconazole) Gel, 2%, VERDESO¬ (desonide) Foam, 0.05%, and MONODOX¬ (doxycycline monohydrate) Capsules. An essential element in Aqua's strategy for strong, sustainable growth is to build beyond the current product portfolio by developing, licensing, and acquiring products for the treatment of skin conditions. Importantly, Aqua looks to expand its opportunities through product development, in-licensing, co-promotion, product or company acquisition, and partnerships. In December 2013, Almirall S.A. entered into a definitive agreement to acquire Aqua Pharmaceuticals. Almirall is a pharmaceutical company committed to provide valuable medicines through its own R&D efforts together with external partnerships, licenses, and collaborations. Through seeking innovative medicines, Almirall aims to be a relevant player in dermatology, in addition to having a strong interest in gastroenterology and pain. With more than 3,000 employees in 23 countries, Almirall generated total revenues of ó825 million in 2013. The company was founded in 1943 and is headquartered in Barcelona, Spain. The stock is traded on the Spanish stock exchange (ticker: ALM).
Pharmaceuticals
50 - 200
Exton, PA, United States
About

Aqua Pharmaceuticals is a specialty dermatology company focusing on acquiring, developing and marketing prescription medical dermatology products in the United States. Currently marketed products include: ACTICLATE¬ (doxycycline hyclate USP) Tablets, CORDRAN¬ (flurandrenolide USP) Lotion, Cream, and Ointment, 0.05%, FLUOROPLEX¬ (fluorouracil) 1% Topical Cream, XOLEGEL¬ (ketaconazole) Gel, 2%, VERDESO¬ (desonide) Foam, 0.05%, and MONODOX¬ (doxycycline monohydrate) Capsules.

An essential element in Aqua's strategy for strong, sustainable growth is to build beyond the current product portfolio by developing, licensing, and acquiring products for the treatment of skin conditions. Importantly, Aqua looks to expand its opportunities through product development, in-licensing, co-promotion, product or company acquisition, and partnerships.

In December 2013, Almirall S.A. entered into a definitive agreement to acquire Aqua Pharmaceuticals. Almirall is a pharmaceutical company committed to provide valuable medicines through its own R&D efforts together with external partnerships, licenses, and collaborations. Through seeking innovative medicines, Almirall aims to be a relevant player in dermatology, in addition to having a strong interest in gastroenterology and pain. With more than 3,000 employees in 23 countries, Almirall generated total revenues of ó825 million in 2013. The company was founded in 1943 and is headquartered in Barcelona, Spain. The stock is traded on the Spanish stock exchange (ticker: ALM).

Site Traffic
  • 28369457 Global Rank
Powered by
Alexa Traffic Data
Global Rank 4,988,338
11,914
Nigeria Rank 108
107
Nigeria Page Views 87.2%
13.3%
Top Countries
Top Search Keywords
  • Industrial Goods and Services
  • Paper
  • Papermakers
  • Tissue and Crepe Papers
They are headquartered at Exton, PA, United States, and have advertising & marketing contacts listed on Kochava. Aqua Pharmaceuticals, An Almirall Company works with Advertising technology companies such as Facebook Custom Audiences, DoubleClick.Net.